Stanislaw Burzynski’s Background and Credentials
Stanislaw Burzynski attended the Medical Academy in Lubin, Poland, where he received an M.D. degree in 1967 and a D.Msc. degree in 1968. He underwent specialty training in cancer and completed several residency programs.
In 1970, Dr. Burzynski came to the United States and worked in the department of anesthesiology at Baylor University, Houston, for three years, isolating peptides from rat brains. He got a license to practice medicine in 1973 and, with others, received a three-year grant to study the effect of urinary peptides on the growth of cancer cells in tissue culture. The grant was not renewed.
In 1976 Burzynski announced a theory for the cure of cancer based on his theory that spontaneous regression occurs because natural anticancer peptides, which he named antineoplastons, “normalize” cancer cells. Since urine contains lots of peptides, he concluded that there he would find antineoplastons. Less than one year later, Dr. Burzynski used an extract from human urine (“antineoplaston A”) to treat 21 cancer patients at a clinic he opened. His shingle read, “Stanislaw R. Burzynski, M.D., Ph.D.”
By 1985, Dr. Burzynski was using eight antineoplastons to treat cancer patients. The first five, which were fractions from human urine, he called A-1 through A-5. From A-2 he made A-10, which was insoluble 3-N-phenylacetylamino piperidine 2,6-dione. He said A-10 was the anticancer peptide common to all his urine fractions. He then treated A-10 with alkali, which yielded a soluble product he named AS-2.5. Further treatment of AS-2.5 with alkali yielded a product he called AS-2.1. Dr. Burzynski is currently treating patients with what he calls “AS-2.1” and “A-10.”